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One of the main concerns
with postprostatectomy RT is
that outcomes can vary,
resulting in inappropriate
treatment. We assessed a
validated genomic classifier
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ical failure (BF) and distant metastasis (DM) in men receiving radiation therapy (RT)
after radical prostatectomy (RP).
Methods and Materials: Among patients who underwent post-RP RT, 139 were iden-
tified for pT3 or positive margin, who did not receive neoadjuvant hormones and had
paraffin-embedded specimens. Ribonucleic acid was extracted from the highest Glea-
son grade focus and applied to a high-density-oligonucleotide microarray. Receiver
operating characteristic, calibration, cumulative incidence, and Cox regression ana-
lyses were performed to assess GC performance for predicting BF and DM after
post-RP RT in comparison with clinical nomograms.
Results: The area under the receiver operating characteristic curve of the Stephenson
model was 0.70 for bothBF andDM,with addition ofGC significantly improving area un-
der the receiver operating characteristic curve to 0.78 and 0.80, respectively. Stratified by
GC risk groups, 8-year cumulative incidence was 21%, 48%, and 81% for BF (P<.0001)immel Cancer Center, Jef-
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Volume 89  Number 5  2014 Genomics predicts failure after radiation 1039differences between adjuvant
and salvage RT were noted
for those with intermediate
or high GC scores but not for
those with low GC scores.and for DM was 0, 12%, and 17% (PZ.032) for low, intermediate, and high GC, respec-
tively. Inmultivariable analysis, patientswithhighGChad ahazard ratio of 8.1 and14.3 for
BF and DM. In patients with intermediate or high GC, those irradiated with undetectable
prostate-specific antigen (PSA 0.2 ng/mL) had median BF survival of >8 years,
compared with<4 years for patients with detectable PSA (>0.2 ng/mL) before initiation
of RT. At 8 years, the DMcumulative incidence for patients with highGC and RTwith un-
detectable PSAwas 3%, compared with 23% with detectable PSA (PZ.03). No outcome
differences were observed for low GC between the treatment groups.
Conclusion: The GC predicted BF and metastasis after post-RP irradiation. Patients
with lower GC risk may benefit from delayed RT, as opposed to those with higher
GC; however, this needs prospective validation. Genomic-based models may be useful
for improved decision-making for treatment of high-risk prostate cancer.
 2014 The Authors. Published by Elsevier Inc.Introduction
Every year, approximately 233,000 men are diagnosed with
prostate cancer (PCa) in the United States, and more than
29,000 men die from this disease annually (1). The vast
majority present with clinically localized disease, and many
undergo radical prostatectomy (RP) as their primary treat-
ment. Although RP is performed with curative intent, a
proportion of these patients will develop PCa recurrence,
particularly those with adverse pathologic features, defined
as positive surgical margin, extraprostatic extension, sem-
inal vesicle involvement (SVI), or detectable post-
prostatectomy prostate-specific antigen (PSA) (2).
Recently, joint consensus guidelines from the American
Urologic Association and the American Society for Radi-
ation Oncology (3) advocated for postprostatectomy adju-
vant radiation in patients at risk for recurrence or with
evidence of progression based on detectable PSA or clinical
progression. However, the guidelines stressed the impor-
tance of a “thoughtful discussion” and a multidisciplinary
approach to balance risks and benefits, reflecting the un-
derlying controversy within the field.
One of the main concerns with postprostatectomy radi-
ation therapy (RT) is that outcomes can vary, and many
men will be subjected to unnecessary adjuvant therapy. In
the 3 prospective, randomized clinical trials examining
adjuvant RT (defined as treatment at the time of undetect-
able PSA) (4-7), approximately 50% of patients random-
ized to observation never developed biochemical failure
(BF), even though some patients had detectable PSA after
RP. Thus, some clinicians would have advocated for
salvage RT as a more selective approach rather than adju-
vant RT. At present there is not yet level 1 evidence to
support the hypothesis that adjuvant and early salvage RT
are equivalent. Further, with salvage RT, 6-year BF-free
survival is approximately 40%, and patients with BF have
a 60% probability of developing distant metastasis (DM)
and 20% probability of PCa-specific death within 10 years
(8). Thus, it is clear that even among a high-risk patient
population based on standard clinical features, there remaina significant proportion of patients who may benefit from
additional local therapy, whereas others may require sys-
temic therapy. On the other hand, studies have shown that
there also exist a significant proportion of patients for
whom the disease progression is indolent and who derive
little benefit from post-RP RT (8, 9).
Novel biomarkers that can improve our prognostic tools
and inform decision making are acutely needed. One such
potential platform is the Decipher genomic classifier (GC)
(GenomeDx Biosciences, San Diego, CA) that uses a whole-
transcriptomemicroarray assay from formalin-fixed, paraffin-
embedded PCa specimens. This signature was developed and
validated as a predictor for clinical metastases after RP in a
cohort of men with adverse features (10). Further, it was
shown to more accurately predict metastases than individual
clinical variables or nomograms (11). Thus, we hypothesized
that incorporation of the GC in clinical models would more
accurately predict BF and DM in men receiving post-RP RT.
Methods and Materials
The Thomas Jefferson University institutional review board
reviewed and approved the research protocol under which
this validation study was conducted. The study met the
PRoBE (12) and REMARK (13) criteria for prospective-
blinded evaluation and analysis of a prognostic biomarker.
Patient cohort
The cohort comprised 143 patients with pT3 or margin-
positive disease, who may have elevated post-RP PSA, and
who underwent post-RP RT at Kimmel Cancer Center,
Thomas Jefferson University between 1999 and 2009. Four
patients who received neoadjuvant hormone therapy were
excluded from the analysis. The GC scores were available
for 139 patients only (Fig. e1, available online). Accounting
for sample loss, there were no significant differences in the
cohort with available GC data in comparison with the
original selected cohort (data not shown). The radiation
techniques including clinical target division definition,
Den et al. International Journal of Radiation Oncology  Biology  Physics1040planning target volume generation, RT techniques, doses,
and volumes have been described previously (14). Further,
the use of hormone therapy and irradiation of pelvic lymph
nodes was performed at the discretion of the treating ra-
diation oncologist.
Specimen selection and processing
After histopathologic review of formalin-fixed, paraffin-
embedded (FFPE) tumor blocks from each case by 2 expert
genitourinary pathologists, the tumor block with the index
lesion was selected for specimen processing. The index
lesion was identified as the prostatectomy FFPE block with
the highest pathologic Gleason grade, regardless of its
volume. Two [x] 0.6-mm diameter tissue biopsy punch tool
cores were sampled to enrich for tumor cells from the
highest Gleason grade in the index lesion and placed in a
microfuge tube for RNA extraction. The RNA extraction
and microarray expression data generation were as previ-
ously described (10). After microarray quality control using
the Affymetrix Power Tools packages (Santa Clara, CA)
(15), probeset summarization and normalization were per-
formed by the SCAN algorithm (16), which normalizes
each batch individually by modeling and removing probe-
and array-specific background noise using only data from
within each array (15).
Calculation of GC scores and nomogram scores
The 22-marker GC was applied to the microarray expression
data for each patient sample as previously described (10). Cut
points for the GC were estimated using receiver operating
characteristic curveebased methods described previously
(11). Cancer of the prostate risk assessment post-surgical
(CAPRA-S) scores were calculated as described by Cooper-
berg et al (17), and Stephenson 5-year survival probabilities
were calculated using the online prediction tool (18).
Statistical analyses
Statistical analyses were performed in R, version 3.0, and
all statistical tests were 2-sided using a 5% significance
level. As previously described, for men who achieved an
undetectable PSA level after surgery, BF was defined as a
PSA 0.4 ng/mL with a subsequent confirmation. For all
other patients, including those with a detectable pre-RT
PSA, BF was defined as 3 increases in PSA measured at
least 6 weeks apart, considering the first PSA rise dated as
the BF; or androgen deprivation therapy due to PSA rise
(14). Undetectable PSA and detectable PSA were defined
as PSA levels of 0.2 and >0.2 ng/mL immediately
before initiation of RT, respectively. Metastatic failure was
defined as DM documented in clinical notes and imaging
reports. In time-to-event analyses, event times were
defined as the time from RT completion date to BF or DM
date.The c2, Wilcoxon, or Fisher exact test were used to test
for association between categoric variables. Area under
receiver operating characteristic curves (AUC), calibration,
and Hosmer-Lemeshow goodness of fit, strip plots, uni-
variable, and multivariable (MVA) Cox proportional hazard
models were used to compare the GC-based and clinical-
only models for predicting BF or DM after RT. The
LASSO method for the Cox model was used for identifi-
cation of the most predictive variables as described previ-
ously (19). Cumulative incidence curves were constructed
using Fine-Gray competing risks analysis (20) to estimate
the risk of BF or DM while accounting for censoring and
death due to other causes.Results
A total of 143 evaluable patients had available archival FFPE
blocks for genome-wide expression analysis. Genomic clas-
sifier scores were generated for 139 patients (97%) (Fig. e1).
Eighty-four percent hadGleason score7 or above; 27%with
Gleason 8-10. Eighty-two percent of men had extraprostatic
extension, 38% had seminal vesicle invasion, and 75% had
positive margins. Fifty-three percent of patients had radiation
initiated when PSA was 0.2 ng/mL, and 21% received ra-
diation with hormonal therapy. The median follow-up times
after RP and after RT were 11.8 and 7.4 years, respectively.
After RT, 54 patients (39%) experienced BF, and 10 (7%)
developed DM on follow-up (Table 1).
The distribution of men among low (<0.4), intermediate
(0.4-0.6), and high (>0.6) GC risk categories was 41%,
38%, and 22%, respectively (Fig. e2). Nearly all patients
who developed DM on follow up (nZ10) had intermediate
or high GC scores (ie, 0.4), except for 1 patient with a
borderline GC score (0.395). The GC scores increased with
higher Gleason score and tumor stage (Fig. e3). Genomic
classifier has a modest correlation to Gleason scores
(r2Z0.29, PZ.0004) and tumor stage (r2Z0.15, PZ.07).
The agreement between observed BF and GC scores
demonstrates virtually perfect calibration of GC for pre-
dicting BF, with a slope of 1.1 and a Hosmer-Lemeshow P
value of .77 (Fig. e4A). We did not observe as good cali-
bration for the post-RT BF endpoint with the Stephenson
model (Fig. e4B). Too few events were available to evaluate
calibration for the DM endpoint.
Receive operator characteristic curve analysis was used
to determine whether GC could improve prediction of
outcome as compared with commonly used clinical risk
prediction models for discrimination of BF and DM events
(Fig. 2A, B). The AUC for the post-RP Stephenson
nomogram was 0.70 (95% confidence interval [CI] 0.61-
0.79) and 0.70 (95% CI 0.49-0.90) for BF and DM end-
points, respectively. For CAPRA-S, the AUC was 0.67
(95% CI 0.58-0.77) and 0.65 (0.44-0.86) for BF and DM
endpoints, respectively. Note that neither clinical nomo-
gram was significantly superior to chance in predicting DM
because the 95% CI included the AUC of 0.5 for a random










Total N 139 85 54
Age (y) .93y
Median 60 60 61
Range (40-76) (40-76) (47-76)
Race .13z
Caucasian 118 (84.9) 68 (80) 50 (93)
Black 18 (13.0) 14 (17) 4 (7)
Hispanic 3 (2.2) 3 (3) 0
Pre-RP PSA (ng/mL) .03x
<10 90 (64.7) 61 (72) 29 (53)
10-20 27 (19.4) 14 (16) 13 (24)
>20 15 (10.8) 6 (7) 9 (17)
Unknown 7 (5.0) 4 (5) 3 (6)
EPE .18y
Positive 114 (82.0) 66 (78) 48 (89)
Unknown 1 (0.7) 1 (1) 0
SVI .16y
Positive 53 (38.1) 28 (33) 25 (46)
Margin 1y
Positive 105 (75.5) 64 (75) 41 (76)
Gleason score .03z
6 21 (15.1) 19 (22) 2 (4)
7 79 (56.9) 49 (58) 30 (56)
8-10 38 (27.3) 16 (19) 22 (40)
Unknown 1 (0.7) 1 (1) 0
Pre-RT PSA (ng/mL) .008z
0.2 74 (53.0) 51 (60) 23 (43)
>0.2-1 36 (26.0) 22 (26) 14 (26)
>1-5 18 (13.0) 7 (8) 11 (20)
> 5 8 (5.8) 2 (2) 6 (11)
Unknown 3 (2.2) 3 (4) 0
Time from RP to RT (mo) .51y
Median 4.57 4.53 4.64
Range (1.08-159.67) (1.77-159.67) (1.08-60.91)
Dose 1y
Median 66.6 66.6 66.6
Range (45-72) (45-72) (60-70.2)
Field .60y
Fossa only 110 (79.1) 69 (81) 41 (76)
Whole pelvic 20 (20.9) 16 (19) 13 (24)
ADT .025y
Positive 29 (20.9) 12 (14) 17 (32)
Abbreviations: ADT Z androgen deprivation therapy;
EPEZ extraprostatic extension; PSAZ prostate-specific antigen; RP
Z radical prostatectomy; RT Z radiation therapy; SM Z surgical
margin; SVI Z seminal vesicle involvement.
* Only 10 patients developed distant metastasis among patients with
biochemical failure.
y Using Pearson c2 test.
z Using Fisher exact test.
x Using Wilcoxon rank sum test.
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0.84) and 0.78 (95% CI 0.64-0.91) for BF and DM
endpoints, respectively. Combining the GC with the Ste-
phenson nomogram improved the AUC to 0.78 (95% CI
0.69-0.86) and 0.80 (95% CI 0.68-0.93) for BF and DM,
respectively (Fig. 1). A similar improvement in AUC was
noted for combining GC with CAPRA-S.Decision curve analysis was used to determine the
clinical utility of the gain in AUC for the GC-based models
(Fig. e5). Compared with scenarios in which no prediction
model would be used for a postoperative RT treatment
decision (ie, “treat all” or “treat none”), the GC-based
models had a higher net benefit than clinical models
across a wide range of decision threshold probabilities
(approximately 20%-75% risk of BF).
Cumulative incidence plots for the probability of BF and
DM show significance for 3 previously reported GC score
risk groups (Fig. 2). The 4-year cumulative incidence of BF
in patients with low, intermediate, and high GC scores was
13%, 31%, and 49%, respectively (Fig. 2A). By 8 years
after RT the difference in BF incidence rates became more
pronounced, with cumulative incidence rates of 21%, 48%,
and 81% for low, intermediate, and high GC score,
respectively (P<.0001). The 8-year cumulative incidence
rates of DM were 0, 12%, and 17% for the GC score
groups. The incidence rates were signficant (PZ.032)
despite the small number of DM events on follow-up in this
cohort (Fig. 2B).
Univariable analysis demonstrated that GC and a num-
ber of clinical factors such as pre-RP PSA level, seminal
vesicle involvement, Gleason score, timing of RT (ie, un-
detectable vs detectable PSA), radiation dose, and
concomitant hormone therapy were all significant pre-
dictors of BF (Tables e1 and e2). Only GC and pre-RP PSA
level were also significant for DM. In MVA analysis GC,
pre-RP PSA level, pathologic Gleason score, and PSA level
prior to RT remained significant predictors of BF (Table 2).
Again, only GC and pre-RP PSA level were significant for
DM. The hazard ratio (HR) for intermediate and high GC
was 2.9 and 8.1 in comparison with the low GC risk group
(Table 2). The HR estimates for the DM endpoint were only
significant for high GC (HR 14.3, PZ.005, although
because of a small number of events it has a wide confi-
dence interval) (21). Further, we validated the findings from
the multiple regression model using penalized regression to
ensure that the significance of GC was not an artifact of few
metastasis events in the MVA analysis. For both BF and
DM, GC was the top variable with a non-zero coefficient,
confirming that GC is the most significant variable and that
the MVA analysis was robust (Fig. e6).
Exploratory analyses were performed to determine
whether GC could predict benefit between those treated
with RT with either undetectable or detectable PSA. We
did not observe the 2 RT groups to differ significantly for
any clinical or treatment variable aside from more
concomitant hormone therapy and a higher proportion of
African Americans in the detectable PSA group (Table
e4). The median time from RP to initiation of RT was
4.21 months (interquartile range, 3.4-5.9) and 6.8 months
(interquartile range, 3.9-25.8) for undetectable and
detectable PSA groups, respectively. Within each GC
score group, for patients with BF GC was higher than for
patients who did not experience BF, regardless of when
RT was initiated (Fig. e7). Cumulative incidence plots for
Fig. 1. Area under the receiver operating characteristic curve (AUC): comparison of genomic classifier (GC)-based and
clinical-only risk models for predicting biochemical failure (A) and distant metastasis (B) after postoperative radiation
therapy. CAPRA-S Z cancer of the prostate risk assessment post-surgical score; CI Z confidence interval.
Den et al. International Journal of Radiation Oncology  Biology  Physics1042BF and DM, comparing undetectable with detectable PSA
RT groups, were stratified by GC risk (Fig. 3). The in-
termediate and high GC score groups were collapsed into
1 group owing to limitations in sample size for this subset
analysis. Within the low GC score group (GC <0.4) there
was no difference in cumulative incidence of BF (Fig. 3A)
or DM (Fig. 3B) for patients who had RT with undetect-
able or detectable PSA. However, for the group with
GC  0.4, a 27% absolute difference in BF was observed
at 8 years, with a median 4-year PSA-free survivalFig. 2. Cumulative incidence plots of biochemical failure (A)
risk genomic classifier (GC) score groups. Cut points were repoadvantage for patients who received RT with undetectable
PSA compared with those with detectable PSA (Fig. 3A).
Patients with GC  0.4 who had detectable PSA when RT
was initiated had a DM cumulative incidence of 23% by
8 years, compared with just 3% for patients with unde-
tectable PSA (Fig. 3B; PZ.03). Similar results were ob-
tained for both BF and DM endpoints in a sensitivity
analysis when considering different PSA level thresholds
(eg, 0.2, 0.21-1, >1.0 ng/mL) at RT initiation (Fig. e8).
Finally, in MVA analysis we were able to estimate theand distant metastasis (B) for low-, intermediate-, and high-
rted previously (29).
Table 2 Multivariable Cox proportional hazards analysis of risk factors for postoperative radiation treatment biochemical failure and
distant metastasis
Risk factor
Biochemical failure Distant metastasis*
HR (95% CI) P HR (95% CI) P
GC Intermediate (Ref: GC < 0.4) 2.88 (1.21-6.85) .02 2.15 (0.18-39.48) .55
GC High (Ref: GC < 0.4) 8.13 (3.40-19.46) <.0001 14.28 (2.13-210.38) .005
Age at RP 1.02 (0.96-1.07) .57 1.01 (0.90-1.15) .9
Caucasian Race (Ref: AAM/Hispanic) 2.31 (0.73-7.31) .16 0.39 (0.05-5.34) .42
(Pre-RP PSA) (log2) 1.49 (1.06-2.10) .02 2.69 (1.33-5.65) .007
EPE (Ref: Negative) 2.04 (0.73-5.66) .17 2.72 (0.21-505) .53
SVI (Ref: Negative) 1.08 (0.50-2.32) .85 0.54 (0.07-2.96) .49
SM (Ref: Negative) 0.68 (0.31-1.46) .32 2 (0.28-18.45) .49
Pathologic Gleason score (Ref: 7) 2.21 (1.07-4.56) .03 2.13 (0.30-14.99) .4
Detectable PSA (Ref: Undetectable PSA) 3.23 (1.49-6.98) .003 0.92 (0.08-10.42) .91
Time between RP and RT (mo) 0.98 (0.96-1.01) .17 1.03 (0.97-1.09) .23
Radiation dose 1.05 (0.91-1.22) .49 1.24 (0.83-1.92) .28
Pelvis radiation (Ref: Fossa only) 0.61 (0.25-1.48) .28 2.1 (0.31-15.93) .44
Concomitant hormone therapy (Ref: None) 1.14 (0.52-2.49) .74 1.44 (0.26-7.24) .66
Abbreviations:AAM Z African American men; CI Z confidence interval; GC Z genomic classifier; HR Z hazard ratio; Ref Z referent. Other
abbreviations as in Table 1.
* Firth’s penalized likelihood method was used due to low number of metastatic events.
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and found that patients with GC  0.4 who had RT with
detectable PSA had an HR of 2.2 (PZ.01) in comparison
with patients with GC  0.4 who had RT with undetect-
able PSA (Table 3). The same trend was observed for the
DM endpoint, with an HR of 7.1 (PZ.07). For GC low
risk patients, no significant differences in hazards were
observed for either endpoint when comparing RT initiated
with undetectable and detectable PSA.
Discussion
Despite the publication of the American Urologic Associa-
tioneAmerican Society for Radiation Oncology consensus
guidelines and 3 phase 3 prospective trials demonstrating the
benefit of adjuvant therapy as opposed to observation, both
in terms of biochemical progressionefree survival as well as
overall survival (Southwest Oncology Group), there remains
controversy regarding the administration of post-
prostatectomy radiation. Two critical factors are that only
50% of patients with adverse pathologic features treated with
surgery alone will develop BF, and even among those pa-
tients with a persistently elevated PSA after prostatectomy,
approximately 10% may never develop clinical metastasesTable 3 Multivariable Cox proportional hazards analysis of risk pre




Detectable PSA (Ref: Undetectable PSA)
GC low-risk subset (<0.4) 2 (0.56-7.12)
GC high-risk subset (0.4) 2.24 (1.19-4.22)
Abbreviation: NA Z not applicable. Other abbreviations as in Tables 1 and
* Cox regression model does not converge, owing to low number of events(22). Given the possibility of overtreatment, many clinicians
are hesitant to initiate additional therapy (23). Currently, 4
prospective randomized clinical trialsdRadiotherapy and
Androgen Deprivation in Combination After Local Surgery
(RADICALS), Radiotherapy Adjuvant versus Early Salvage
(RAVES), GETUG-17, and European Organization for
Research and Treatment of Cancer 22,043-30,031dare
investigating the therapeutic benefit of early salvage RTwith
or without androgen deprivation therapy compared with
adjuvant RT.
This study provides critical insight into disease aggres-
siveness, which can have major ramifications for the inter-
pretation of these forthcoming trials. Herein we provide the
first validation of the GC score in the postprostatectomy RT
setting. We demonstrated that within a group of patients with
high-risk features for BF and development of DM, the GC
score was able to differentiate outcomes. The GC score
improved risk stratification above known clinical classifiers,
specifically in terms of development of DM. Moreover, our
data suggest that for patients with low GC scores outcomes
were not different for men receiving adjuvant versus salvage
RT; for those men with intermediate- or high-risk GC the
timing of RT initiation in terms of PSA levels significantly
altered BF and DM survival outcomes.diction models for postoperative radiation treatment biochemical
is (BF) Multivariable analysis (DM)
P HR (95% CI) P
.29 NA* NA
.01 7.12 (0.89-57.09) .07
2.
(events Z 1 out of 10).
Fig. 3. Cumulative incidence plots of biochemical failure and distant metastasis comparing patients treated with radiation
therapy (RT) when prostate-specific antigen (PSA) was undetectable (A, C) and detectable (B, D), as stratified by genomic
classifier (GC) score risk groups.
Den et al. International Journal of Radiation Oncology  Biology  Physics1044Given the high cumulative incidence of BF and DM in
particular, for the high GC score patient group, this is a
patient population in whom exploration of intensification of
therapy would be warranted. In an unselected patient pop-
ulation, postprostatectomy radiation combined with anti-
androgen therapy has been demonstrated to improve
freedom from BF as well as reduce the incidence of met-
astatic PCa (24) in comparison with radiation monotherapy.
A subsequent phase 2 trial examining adjuvant docetaxel
after androgen deprivation and RT for high-riskpostprostatectomy patients is closed, with results expected
within the next several years. With the plethora of new
agents approved for metastatic castrate-resistant PCa (25-
30) on the basis of improvements in overall survival,
there are a variety of combinations that can be examined
clinically. As such, defining those patients most at risk for
local treatment failure is critical because many of these
therapies have potential morbidity associated with them.
There are several limitations in the present study. First,
there were few DM noted in this patient population. As
Volume 89  Number 5  2014 Genomics predicts failure after radiation 1045such, full analysis of DM as an endpoint was limited.
Further, this is a retrospective analysis from a single
institution, and this data set only included patients
receiving RT, and as such, examining whether outcomes
from patients treated with observation alone would mimic
those treated with RT, particularly for those patients with
low GC score, is beyond the scope of this analysis. In
addition, some patients received early adjuvant RT, whereas
others received later salvage therapy, according to both
physician as well as patient preference. The use of
androgen deprivation therapy was not universal and re-
flected inherent biases among the treating physicians.
However, this does reflect current treatment practices.
The data presented in this study confirm and extend the
prior publications demonstrating the predictive capability
and utility of the GC score (10, 11) beyond clinicopatho-
logic parameters. The use of a genomic signature has been
demonstrated to alter clinical decision making in approxi-
mately 50% of cases (31), indicating the potential broad
clinical impact. Further, both GC score and clinical factors
independently associated with BF and DM in MVA anal-
ysis, implying that genomic risk classifiers can be incor-
porated with added value into clinical care. Furthermore,
when translating genomic risk classifiers into clinical
practice, it is important that the added information be
supplemented with traditional clinical parameters to guide
decision making. It is expected that low-risk GC scores in
patients with adverse pathology could be used to guide
treatment decisions for possibly delayed or deferred irra-
diation when risk of failure is low. This may benefit patients
incontinent of urine, who require additional time to heal
after RP or those in whom daily radiation may be
burdensome. Given the increasing incidence and costs of
PCa treatments (32), avoidance of unnecessary or inade-
quate treatment would have major implications for the
healthcare system and limit the potential overtreatment of
patients who will not recur or progress. These observations
are particularly salient given the ongoing randomized
controlled trials of adjuvant versus early salvage radiation
therapy because our results demonstrate 2 distinct groups of
patients, who are currently not stratified in the trial designs.References
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